GLOBRYTE: A Phase III, Open-label, Multicenter, Randomized Trial Evaluating Glofitamab Monotherapy in Patients with Relapsed or Refractory Mantle Cell Lymphoma

被引：0
|
作者：
Phillips, Tycel [1 ]
Matasar, Matthew [2 ]
Eyre, Toby A. [3 ]
Gine, Eva [4 ]
de L'Etang, Audrey Filezac [5 ]
Byrne, Ben [6 ]
Lundberg, Linda [5 ]
Padovani, Alejandra [5 ]
Boetsch, Christophe [5 ]
Bottos, Alessia [5 ]
Qayum, Naseer [6 ]
机构：
[1] City Hope Natl Med Ctr, Duarte, CA USA
[2] Rutgers Canc Inst New Jersey, New Brunswick, NJ USA
[3] Oxford Univ Hosp NHS Trust, Oxford, England
[4] Hosp Clin Barcelona, Barcelona, Spain
[5] F Hoffmann La Roche Ltd, Basel, Switzerland
[6] Roche Prod Ltd, Welwyn Garden City, Herts, England
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2024年 / 24卷
关键词：
MCL; clinical trials; non-Hodgkin lymphoma; bispecific antibody therapy; adverse events; mantle cell lymphoma; phase; 3;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
MCL-339
引用
收藏
页码：S515 / S515
页数：1
相关论文
共 50 条
  • [31] Results of a nonrandomized, open-label, phase II study of combined gemcitabine, mitoxantrone, and rituximab in relapsed or refractory mantle cell lymphoma
    Garbo, Lawrence E.
    Flynn, Patrick J.
    MacRae, Margaret A.
    Rauch, Mary A.
    Wang, Yunfei
    Kolibaba, Kathryn S.
    BLOOD, 2007, 110 (11) : 183B - 183B
  • [32] Panobinostat in combination with bortezomib in patients with relapsed or refractory peripheral T-cell lymphoma: an open-label, multicentre phase 2 trial
    Tan, Daryl
    Phipps, Colin
    Hwang, William Y. K.
    Tan, Soo Yong
    Yeap, Chun Hsien
    Chan, Yiong Huak
    Tay, Kevin
    Lim, Soon Thye
    Lee, Yuh Shan
    Kumar, Sathish Gopalakrishnan
    Ng, Soo Chin
    Fadilah, S.
    Kim, Won Seog
    Goh, Yeow Tee
    LANCET HAEMATOLOGY, 2015, 2 (08): : E326 - E333
  • [33] Loncastuximab tesirine in Chinese patients with relapsed or refractory diffuse large B-cell lymphoma: a multicenter, open-label, single-arm, phase II trial
    Lin, Ningjing
    Sun, Xiuhua
    Zhou, Hui
    Zou, Liqun
    Zhou, Keshu
    Liu, Lihong
    Yang, Haiyan
    Hu, Kai
    Cai, Qingqing
    Liu, Yao
    Jin, Jie
    Zhang, Liling
    Li, Wenyu
    Guo, Ye
    Yang, Wei
    Luo, Feng
    Wang, Zhenguang
    Zhu, Rong
    Yang, Lei
    Song, Dan
    Song, Yuqin
    Zhu, Jun
    HAEMATOLOGICA, 2025, 110 (03) : 683 - 692
  • [34] MagnetisMM-5: An open-label, multicenter, randomized phase 3 study of elranatamab as monotherapy and in combination with daratumumab in patients with relapsed/refractory multiple myeloma.
    Grosicki, Sebastian
    Crafoord, Jacob
    Koh, Youngil
    White, Darrel
    Mellqvist, Ulf-Henrik
    Leip, Eric
    Kudla, Arthur
    Finn, Gregory
    Pruchniewski, Lukasz
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [35] Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial
    Morschhauser, Franck
    Tilly, Herve
    Chaidos, Aristeidis
    McKay, Pamela
    Phillips, Tycel
    Assouline, Sarit
    Batievi, Connie Lee
    Campbell, Phillip
    Ribrag, Vincent
    Damaj, Gandhi Laurent
    Dickinson, Michael
    Jurczak, Wojciech
    Kazmierczak, Maciej
    Opat, Stephen
    Radford, John
    Schmitt, Anna
    Yang, Jay
    Whalen, Jennifer
    Agarwal, Shefali
    Adib, Deyaa
    Salles, Gilles
    LANCET ONCOLOGY, 2020, 21 (11): : 1433 - 1442
  • [36] An Open-Label Phase II Study of Buparlisib (BKM120) in Patients with Relapsed and Refractory Diffuse Large B-Cell Lymphoma, Mantle Cell Lymphoma or Follicular Lymphoma
    Younes, Anas
    Salles, Gilles
    Bociek, R. Gregory
    Martinelli, Giovanni
    Caballero, Dolores
    Gonzalez Barca, Eva
    Mukherjee, Nabanita
    Williams, Lisa
    Herbst, Fabian
    Tavorath, Ranjana
    Kim, Won Seog
    BLOOD, 2014, 124 (21)
  • [37] Alectinib for relapsed or refractory anaplastic lymphoma kinase-positive anaplastic large cell lymphoma: An open-label phase II trial
    Fukano, Reiji
    Mori, Tetsuya
    Sekimizu, Masahiro
    Choi, Ilseung
    Kada, Akiko
    Saito, Akiko Moriya
    Asada, Ryuta
    Takeuchi, Kengo
    Terauchi, Takashi
    Tateishi, Ukihide
    Horibe, Keizo
    Nagai, Hirokazu
    CANCER SCIENCE, 2020, 111 (12) : 4540 - 4547
  • [38] Glofitamab Monotherapy In Patients With Heavily Pretreated Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL): Updated Analysis From A Phase 1/2 Study
    Phillips, Tycel
    Carlo-Stella, Carmelo
    Morschhauser, Franck
    Bachy, Emmanuel
    Crump, Michael
    Trneny, Marek
    Bartlett, Nancy L.
    Zaucha, Jan
    Wrobel, Tomasz
    Offner, Fritz
    de L'Etang, Audrey Filezac
    Relf, James
    Carlile, David J.
    Byrne, Ben
    Mulvihill, Estefania
    Lundberg, Linda
    Dickinson, Michael
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S515 - S516
  • [39] Ibrutinib as Treatment for Patients With Relapsed/Refractory Follicular Lymphoma: Results From the Open-Label, Multicenter, Phase II DAWN Study
    Gopal, Ajay K.
    Schuster, Stephen J.
    Fowler, Nathan H.
    Trotman, Judith
    Hess, Georg
    Hou, Jing-Zhou
    Yacoub, Abdulraheem
    Lill, Michael
    Martin, Peter
    Vitolo, Umberto
    Spencer, Andrew
    Radford, John
    Jurczak, Wojciech
    Morton, James
    Caballero, Dolores
    Deshpande, Sanjay
    Gartenberg, Gary J.
    Wang, Shean-Sheng
    Damle, Rajendra N.
    Schaffer, Michael
    Balasubramanian, Sriram
    Vermeulen, Jessica
    Cheson, Bruce D.
    Salles, Gilles
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (23) : 2405 - +
  • [40] Glofitamab monotherapy in patients with heavily pretreated relapsed/refractory (R/R) mantle cell lymphoma (MCL): Updated analysis from a phase I/II study
    Phillips, Tycel Jovelle
    Carlo-Stella, Carmelo
    Morschhauser, Franck
    Bachy, Emmanuel
    Crump, Michael
    Trneny, Marek
    Bartlett, Nancy L.
    Zaucha, Jan
    Wrobel, Tomasz
    Offner, Fritz
    de L'Etang, Audrey Filezac
    Relf, James
    Carlile, David J.
    Byrne, Ben
    Mulvihill, Estefania
    Lundberg, Linda
    Dickinson, Michael
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
12345